Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2710391 | 0.95 | PPARA (0.61) | FFAR1L3MBTL1LMNAPPARALTA4H | |
| SCHEMBL854425 | 0.91 | L3MBTL1 (0.65) | FFAR1L3MBTL1LMNAPPARAFFAR4 | |
| SCHEMBL31448501 | 0.88 | PPARA (0.65) | FFAR1L3MBTL1LMNAPPARAFFAR4 | |
| SCHEMBL10728695 | 0.85 | PLA2G4B (0.59) | FFAR1L3MBTL1LMNAPPARAPPARG | |
| SCHEMBL8449777 | 0.85 | LTA4H (0.50) | FFAR1L3MBTL1LMNALTA4H | |
| SCHEMBL7565477 | 0.84 | FFAR1 (0.67) | FFAR1L3MBTL1LMNAPPARAFFAR4 | |
| SCHEMBL10207287 | 0.84 | LMNA (0.63) | FFAR1L3MBTL1LMNAPPARAFFAR4 | |
| SCHEMBL31448470 | 0.82 | PPARA (0.73) | FFAR1L3MBTL1LMNAPPARA | |
| SCHEMBL16902877 | 0.82 | HRH3 (0.59) | L3MBTL1LMNALTA4H | |
| SCHEMBL8545935 | 0.82 | HRH3 (0.59) | FFAR1L3MBTL1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227813-B1 | REVERSE-TURN MIMETICS AS alpha 4ß INTEGRIN INHIBITORS | MYRIAD GENETICS INC (US) | 2007-08-22 | — | — | EP | claimed |
| CN-108770357-B | Polymer conjugate vaccines | 芝加哥大学 | 2022-10-28 | — | — | CN | disclosed |
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2015-02-26 | — | — | US | disclosed |
| US-8729262-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8318738-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-11-27 | — | — | US | disclosed |
| US-20100216992-A1 | MIMETIC COMPOSITIONS AND THE PRODUCTION THEREOF | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-08-26 | — | — | US | disclosed |
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7598253-B2 | Reverse-turn mimetics and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-0962537-B1 | Methods for analyzing nucleic acid molecules utilizing sizing techniques | OPERON BIOTECHNOLOGIES INC (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-0992511-B1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES INC (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | disclosed |
| US-5773001-A | ANTIGROWTH AGENTS | AMERICAN CYANAMID COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| US-5767285-A | USEFUL FOR CONSTRUCTING DRUG CONJUGATES; ANTIBIOTIC ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0840804-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | DARWIN MOLECULAR CORPORATION (US) | 1998-05-13 | — | — | EP | disclosed |
| US-5739116-A | DISULFIDE DERIVATIVE OF CALICHEAMICIN FAMILY; ANTITUMOR ANTIBIOTICS | AMERICAN CYANAMID COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | disclosed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027325-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0689845-A2 | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis | AMERICAN CYANAMID COMPANY (US) | 1996-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216992-A1 | MIMETIC COMPOSITIONS AND THE PRODUCTION THEREOF | BID, BCL2L1, BCL2A1 | FFAR1 4437/4885L3MBTL1 1107/4885LMNA 2348/4885 |
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | FFAR1 3408/4885L3MBTL1 1783/4885LMNA 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.